Compare JKS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JKS | PHVS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2010 | 2021 |
| Metric | JKS | PHVS |
|---|---|---|
| Price | $29.73 | $24.93 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $19.49 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 679.0K | 240.7K |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,641,756,390.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $36.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.42 | $11.51 |
| 52 Week High | $31.88 | $29.80 |
| Indicator | JKS | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 47.90 |
| Support Level | $26.51 | $25.28 |
| Resistance Level | $30.90 | $26.68 |
| Average True Range (ATR) | 1.36 | 1.53 |
| MACD | 0.19 | -0.07 |
| Stochastic Oscillator | 76.94 | 29.94 |
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.